Bunazosin Hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329209

CAS#: 52712-76-2 (HCl)

Description: Bunazosin Hydrochloride, also known as Andante and E-643, is an alpha(1)-adrenoceptor antagonist used as a systemic antihypertensive and an ocular hypotensive drug.

Price and Availability


USD 90
USD 450
USD 2150

USD 150
USD 750
USD 3650

USD 250
USD 1250
Not available

Bunazosin Hydrochloride, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 329209
Name: Bunazosin Hydrochloride
CAS#: 52712-76-2 (HCl)
Chemical Formula: C19H28ClN5O3
Exact Mass:
Molecular Weight: 409.915
Elemental Analysis: C, 55.67; H, 6.89; Cl, 8.65; N, 17.09; O, 11.71

Related CAS #: 80755-51-7(free base)   52712-76-2 (HCl)    

Synonym: Bunazosin Hydrochloride; E-643; E-1015; E 643; E 1015; E643; E1015; Andante

IUPAC/Chemical Name: 1-(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl)butan-1-one hydrochloride


InChi Code: InChI=1S/C19H27N5O3.ClH/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19;/h11-12H,4-10H2,1-3H3,(H2,20,21,22);1H


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information


1: Goto W, Ichikawa M, Tanaka E, Hara H, Araie M. Bunazosin hydrochloride reduces glutamate-induced neurotoxicity in rat primary retinal cultures. Brain Res. 2004 Apr 2;1003(1-2):130-7. PubMed PMID: 15019572.

2: Kobayashi H, Kobayashi K, Okinami S. Efficacy of bunazosin hydrochloride 0.01% as adjunctive therapy of latanoprost or timolol. J Glaucoma. 2004 Feb;13(1):73-80. PubMed PMID: 14704548.

3: Yoshikawa K, Katsushima H, Kimura T, Yamagishi K, Yamabayashi S. Addition of or switch to topical bunazosin hydrochloride in elderly patients with normal-tension glaucoma: A one-year follow-up study. Jpn J Ophthalmol. 2006 Sep-Oct;50(5):443-8. PubMed PMID: 17013697.

4: Okada Y, Ichikawa M, Ishii K, Hara H. Effects of topically instilled bunazosin hydrochloride and other ocular hypotensive drugs on endothelin-1-induced constriction in rabbit retinal arteries. Jpn J Ophthalmol. 2004 Sep-Oct;48(5):465-9. PubMed PMID: 15486769.

5: Hara H, Ichikawa M, Oku H, Shimazawa M, Araie M. Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56. Review. PubMed PMID: 15867947.

6: Mochizuki Y, Oishi M, Takasu T. Effects of bunazosin hydrochloride sustained-release formulation on cerebral circulation. Int Angiol. 2000 Mar;19(1):35-8. PubMed PMID: 10853683.

7: Akaishi T, Takagi Y, Matsugi T, Ishida N, Hara H, Kashiwagi K. Effects of bunazosin hydrochloride on ciliary muscle constriction and matrix metalloproteinase activities. J Glaucoma. 2004 Aug;13(4):312-8. PubMed PMID: 15226660.

8: Goto W, Oku H, Okuno T, Sugiyama T, Ikeda T. Amelioration by topical bunazosin hydrochloride of the impairment in ocular blood flow caused by nitric oxide synthase inhibition in rabbits. J Ocul Pharmacol Ther. 2003 Feb;19(1):63-73. PubMed PMID: 12648305.

9: Hu WY, Fukuda N, Soma M, Izumi Y, Kanmatsuse K. Bunazosin hydrochloride inhibits exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats by suppressing the response to growth factors. J Cardiovasc Pharmacol. 1998 Dec;32(6):975-82. PubMed PMID: 9869504.

10: Yang SC, Tsai WI, Liau CS, Wang TD. Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. Acta Cardiol Sin. 2013 Jan;29(1):11-8. PubMed PMID: 27122680; PubMed Central PMCID: PMC4804956.

11: Ichikawa M, Okada Y, Asai Y, Hara H, Ishii K, Araie M. Effects of topically instilled bunazosin, an alpha1-adrenoceptor antagonist, on constrictions induced by phenylephrine and ET-1 in rabbit retinal arteries. Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4041-8. PubMed PMID: 15505054.

12: Goto W, Oku H, Okuno T, Sugiyama T, Ikeda T. Amelioration of endothelin-1-induced optic nerve head ischemia by topical bunazosin. Curr Eye Res. 2005 Feb;30(2):81-91. PubMed PMID: 15814466.

13: Lee AS, Chen WP, Su MJ. Comparison of the cardiac electrophysiological effects between doxazosin and bunazosin. J Biomed Sci. 2008 Jul;15(4):519-28. doi: 10.1007/s11373-008-9249-8. PubMed PMID: 18427952.

14: Sugiyama T, Oku H, Moriya S, Shimizu K, Azuma I. [Evaluation of bunazosin hydrochloride with a model of ocular circulation disturbance induced by endothelin-1]. Nippon Ganka Gakkai Zasshi. 1994 Jan;98(1):63-8. Japanese. PubMed PMID: 7906490.

15: Aihara M, Araie M, Kaburaki T, Shirato S. [Effects of long-term application of bunazosin hydrochloride eye drops on the aqueous flow rate and blood-aqueous barrier permiability in rabbit eyes]. Nippon Ganka Gakkai Zasshi. 1994 Jun;98(6):540-4. Japanese. PubMed PMID: 7913288.